ZIMHI® (naloxone) is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adult and pediatric patients. ZIMHI is intended for immediate administration as emergency therapy in settings where opioids may be present. ZIMHI is not a substitute for emergency medical care.
ZIMHI Technology – watch our video that explains how it works
Want to learn more?
Read our press release go to our Investor Relations page or visit https://dmkpharma.com/
Check this page for the most recent updates regarding the merger process.